Improving Diagnosis of Primary Biliary Cirrhosis with Anti-Mitochondrial Antibodies
Author Information
Author(s): Hiroshi Miyakawa, Atsushi Tanaka, Carlo Selmi, Naomi Hosoya, Norikazu Mataki, Kentaro Kikuchi, Takashi Kato, Junya Arai, Toshihiro Goto, M. Eric Gershwin
Primary Institution: Teikyo University School of Medicine
Hypothesis
Non-PBC reactivities with lysates from E. coli overexpressing recombinant PDC-E2 might be secondary to low-affinity antibody binding to bacterial proteins, rather than the overexpressed human motif.
Conclusion
Weak cross-reactivity with E. coli PDC-E2 occurs in non-PBC sera at lower dilutions, and using a specific buffer can reduce false positive AMA determinations.
Supporting Evidence
- 100% of anti-PDC-E2-positive PBC sera recognized E. coli PDC-E2.
- Non-PBC sera showed weak reactivity that was lost after adsorption with a synthetic peptide.
- The unique buffer reduced non-specific reactivity in non-PBC sera.
Takeaway
Doctors found that some blood tests for liver disease can show false positives because of similar proteins in bacteria, but using a special solution can help fix this.
Methodology
The study analyzed serum samples from patients with primary biliary cirrhosis and controls using immunoblotting and ELISA with E. coli lysates.
Potential Biases
Potential bias in the selection of serum samples and the interpretation of immunoblotting results.
Limitations
The study's findings are based on a limited sample size and may require further validation in larger populations.
Participant Demographics
The study included 24 patients with primary biliary cirrhosis and 53 controls (16 with autoimmune hepatitis, 10 with primary sclerosing cholangitis, and 27 healthy individuals).
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website